Effectiveness of the XBB.1.5 COVID-19 Vaccines Against
SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During
the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study,
Europe, November 2023 to May 2024

J 2025

Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

ANTUNES, Liliana; Madelyn ROJAS-CASTRO; Marcos LOZANO; Ivan MARTINEZ-BAZ; Isabel LEROUX-ROELS et. al.

Základní údaje

Originální název

Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

Autoři

Vydání

Influenza and Other Respiratory Viruses, Hoboken, Wiley, 2025, 1750-2640

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30303 Infectious Diseases

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.200 v roce 2024

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1111/irv.70081

UT WoS

001439980000001

EID Scopus

2-s2.0-105000000594

Klíčová slova anglicky

case-control study; elderly; severe acute respiratory infections (SARI); test-negative design; vaccine effectiveness

Štítky

14110214, 14110516, 14119710

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 4. 2025 08:43, Mgr. Tereza Miškechová

Anotace

V originále

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (>= 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.

Citovat

ANTUNES, Liliana; Madelyn ROJAS-CASTRO; Marcos LOZANO; Ivan MARTINEZ-BAZ; Isabel LEROUX-ROELS; Maria-Louise BORG; Beatrix OROSZI; Margaret FITZGERALD; Ralf DUERRWALD; Ligita JANCORIENE; Ausenda MACHADO; Goranka PETROVIC; Mihaela LAZAR; Lenka SOUČKOVÁ; Sabrina BACCI; Jennifer HOWARD; Nuno VERDASCA; Luca BASILE; Jesus CASTILLA; Silke TERNEST; Ausra DZIUGYTE; Gergo TURI; Roisin DUFFY; Carolin HACKMANN; Monika KULIESE; Veronica GOMEZ; Zvjezdana Lovric MAKARIC; Alexandru MARIN; Petr HUSA; Nathalie NICOLAY; Angela M C ROSE a VEBIS SARI VE network TEAM. Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza and Other Respiratory Viruses. Hoboken: Wiley, 2025, roč. 19, č. 3, s. 1-7. ISSN 1750-2640. Dostupné z: https://doi.org/10.1111/irv.70081.

@article{2488660,
   author = {Antunes, Liliana and RojasandCastro, Madelyn and Lozano, Marcos and MartinezandBaz, Ivan and LerouxandRoels, Isabel and Borg, MariaandLouise and Oroszi, Beatrix and Fitzgerald, Margaret and Duerrwald, Ralf and Jancoriene, Ligita and Machado, Ausenda and Petrovic, Goranka and Lazar, Mihaela and Součková, Lenka and Bacci, Sabrina and Howard, Jennifer and Verdasca, Nuno and Basile, Luca and Castilla, Jesus and Ternest, Silke and Dziugyte, Ausra and Turi, Gergo and Duffy, Roisin and Hackmann, Carolin and Kuliese, Monika and Gomez, Veronica and Makaric, Zvjezdana Lovric and Marin, Alexandru and Husa, Petr and Nicolay, Nathalie and Rose, Angela M C and team, VEBIS SARI VE network},
   article_location = {Hoboken},
   article_number = {3},
   doi = {https://doi.org/10.1111/irv.70081},
   keywords = {case-control study; elderly; severe acute respiratory infections (SARI); test-negative design; vaccine effectiveness},
   language = {eng},
   issn = {1750-2640},
   journal = {Influenza and Other Respiratory Viruses},
   title = {Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/irv.70081},
   volume = {19},
   year = {2025}
}

TY  - JOUR
ID  - 2488660
AU  - Antunes, Liliana - Rojas-Castro, Madelyn - Lozano, Marcos - Martinez-Baz, Ivan - Leroux-Roels, Isabel - Borg, Maria-Louise - Oroszi, Beatrix - Fitzgerald, Margaret - Duerrwald, Ralf - Jancoriene, Ligita - Machado, Ausenda - Petrovic, Goranka - Lazar, Mihaela - Součková, Lenka - Bacci, Sabrina - Howard, Jennifer - Verdasca, Nuno - Basile, Luca - Castilla, Jesus - Ternest, Silke - Dziugyte, Ausra - Turi, Gergo - Duffy, Roisin - Hackmann, Carolin - Kuliese, Monika - Gomez, Veronica - Makaric, Zvjezdana Lovric - Marin, Alexandru - Husa, Petr - Nicolay, Nathalie - Rose, Angela M C - team, VEBIS SARI VE network
PY  - 2025
TI  - Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
JF  - Influenza and Other Respiratory Viruses
VL  - 19
IS  - 3
SP  - 1-7
EP  - 1-7
PB  - Wiley
SN  - 17502640
KW  - case-control study
KW  - elderly
KW  - severe acute respiratory infections (SARI)
KW  - test-negative design
KW  - vaccine effectiveness
UR  - https://onlinelibrary.wiley.com/doi/10.1111/irv.70081
N2  - We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (>= 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.
ER  -

ANTUNES, Liliana; Madelyn ROJAS-CASTRO; Marcos LOZANO; Ivan MARTINEZ-BAZ; Isabel LEROUX-ROELS; Maria-Louise BORG; Beatrix OROSZI; Margaret FITZGERALD; Ralf DUERRWALD; Ligita JANCORIENE; Ausenda MACHADO; Goranka PETROVIC; Mihaela LAZAR; Lenka SOUČKOVÁ; Sabrina BACCI; Jennifer HOWARD; Nuno VERDASCA; Luca BASILE; Jesus CASTILLA; Silke TERNEST; Ausra DZIUGYTE; Gergo TURI; Roisin DUFFY; Carolin HACKMANN; Monika KULIESE; Veronica GOMEZ; Zvjezdana Lovric MAKARIC; Alexandru MARIN; Petr HUSA; Nathalie NICOLAY; Angela M C ROSE a VEBIS SARI VE network TEAM. Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. \textit{Influenza and Other Respiratory Viruses}. Hoboken: Wiley, 2025, roč.~19, č.~3, s.~1-7. ISSN~1750-2640. Dostupné z: https://doi.org/10.1111/irv.70081.

Přehled o publikaci